This study evaluates the safety and potential therapeutic activity of JadiCell™, an investigational umbilical cord-derived mesenchymal stem cell therapy, in patients diagnosed with Acute Respiratory Distress Syndrome (ARDS). JadiCells are administered intravenously and are intended to modulate inflammatory responses and promote tissue repair in injured lung tissue.

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammatory lung injury, impaired oxygen exchange, and high mortality. Current treatments are primarily supportive and include mechanical ventilation and intensive care management.

JadiCell™ is an investigational cellular therapy derived from human umbilical cord tissue. These cells possess immunomodulatory and regenerative properties and may reduce inflammatory lung injury through paracrine signaling, immune regulation, and tissue repair mechanisms.

Following intravenous administration, mesenchymal stem cells are known to localize within the pulmonary microvasculature where they interact with immune cells and injured lung tissue.

This study will evaluate the safety and potential clinical effects of intravenous JadiCell administration in patients with ARDS.

Inclusion Criteria:

1. Patients currently hospitalized
2. Laboratory confirmation of ARDS
3. Aged between 18 and 80 years
4. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent
5. SpO2 <94% on room air requiring supplemental oxygen above baseline
6. PaO2/FiO2 <300 mmHg
7. Bilateral infiltrates on frontal chest radiograph or bilateral ground glass opacities on a chest CT scan
8. Requiring one of the following ï High Flow Oxygen Therapy ï Non-invasive Positive Pressure Ventilation (NIPPV, e.g. BiPAP and CPAP) ï Invasive Mechanical Ventilation (INV = intubated)

Exclusion Criteria:

1. Greater than 96 h since hospitalization at the time of enrollment
2. Greater than 48 h since intubation at the time of enrollment
3. A previous MSC infusion not related to this trial
4. History of Pulmonary Hypertension (WHO Class III/IV)
5. History of left atrial hypertension or decompensated left heart failure.
6. Pregnant or lactating patient
7. Unstable arrhythmia
8. Patients currently receiving immunosuppression with exception of up to 10 mg Prednisone equivalents daily
9. Patients currently receiving chronic dialysis
10. Patients currently receiving Extracorporeal Membrane Oxygenation (ECMO)
11. Presence of any active malignancy (except non-melanoma skin cancer)
12. Moderate to severe liver disease (AST and ALT >5 X ULN)
13. Severe chronic respiratory disease with a PaCO2 > 50 mm Hg or the use of home oxygen at rest
14. Septic Shock (with >1 vasopressor)
15. Multi-organ failure
16. Not expected to survive > 48 hours